Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
Online Exclusive Article

Moxetumomab Pasudotox: Clinical Experience in Relapsed/Refractory Hairy Cell Leukemia

Julie Feurtado
Robert J. Kreitman
CJON 2019, 23(3), E52-E59 DOI: 10.1188/19.CJON.E52-E59

Background: Moxetumomab pasudotox is a promising new therapy for the treatment of patients with relapsed/refractory hairy cell leukemia (R/R HCL), but practical guidance relating to its administration is limited.

Objectives: This article describes clinical guidelines for the administration of moxetumomab pasudotox to patients with R/R HCL and presents related case studies.

Methods: A limited review of the literature on HCL was undertaken.

Findings: Nursing care of patients prescribed moxetumomab pasudotox includes monitoring clinical and laboratory parameters, managing side effects, being aware of signs of serious side effects, and maintaining patient hydration during administration.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or